Intellia Therapeutics Ends Co-Development Agreement With Regeneron

By Chris Wack

Intellia Therapeutics said in a filing that it has notified Regeneron Pharmaceuticals that it is opting out of its Factor IX co-development and co-funding agreement, which Intellia and Regeneron entered into in May 2020.

The agreement will end 180 days after Intellia's written notice to Regeneron, and the company will continue to have obligations related to the co-development of gene-editing products directed to Factor IX until the effective date of termination.

Upon termination, Intellia will no longer be obligated for sharing 35% of the development costs, or be entitled to receive 35% of the profits, for gene-editing products.

Intellia will continue to support Regeneron with the development of gene-editing products under a previous license and collaboration agreement.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

03-22-24 1023ET